Verastem, Inc. - Common Stock (VSTM)

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025.

VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!

The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.